Genentech’s phase III IMmotion151 study met its co-primary endpoint ofprogression-free survival and demonstrated that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death in people whose disease expressed the PD-L1 (PD-L1 expression ≥1 percent) protein compared with sunitinib for the first-line treatment of people who have advanced or metastatic renal cell carcinoma.
Research from Children’s Medical Center Research Institute at UT Southwestern shows that metastatic kidney cancers rely heavily on mitochondrial metabolism. These findings are contrary to how tumors operate while still in the kidney.Â
